Drug-induced hypersomnia

• Main Authors: T. M. Ostroumova, O. D. Ostroumova, A. V. Filippova, T. F. Guseva
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2021-04-01
• Series: Nevrologiâ, Nejropsihiatriâ, Psihosomatika
• Subjects: hypersomnia; drug-induced hypersomnia; medication; adverse drug reaction; side effects
• Online Access: https://nnp.ima-press.net/nnp/article/view/1550

Daytime somnolence may be a symptom of different somatic,  neurological and psychiatric diseases and develop due to abuse  and/or discontinuation of various medications. Drug- induced hypersomnia (DIH) is defined as hypersomnolence  caused by the intake of multiple drugs. DIH is one of the most frequently reported effects and/or side effects of drugs. DIH  prevalence varies widely and can be as high as 75% in patients receiving specific medications. DIH risk factors include elderly  and senile age, impaired drug metabolism, serum drug  concentration, method and frequency of drug administration, single and daily doses of drugs, etc., as in many other drug- induced diseases and syndromes. DIH can occur both due to sedative agents administration and withdrawal of  psychostimulants and other activating psychotropic  medications. Most often, the development of DIH is associated with the use of levodopa-carbidopa, antipsychotics,  antidepressants. The pathogenesis of DIH is complex and multifactorial and is associated with the mechanism of action of  individual drugs and the presence of concomitant diseases. The  article discusses the risk assessment of DIH development due to  various medications, diagnosis and management tactics of  patients with DIH.